β-arrestins: Regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia

Handbook of Experimental Pharmacology

Volumn 219, Issue , 2014, Pages 427-443

  Raehal, Kirsten M ^a,b   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

Analgesia; Antinociception; Arrestin; Cannabinoid; Cannabinoid CB1 receptor; Mu opioid receptor; Opioid; Pain; Tolerance

Indexed keywords

BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HERKINORIN; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR; TRV 130; UNCLASSIFIED DRUG; 1 BUTYL 3 (1 NAPHTHOYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR AGONIST; ETORPHINE; FENTANYL; G PROTEIN COUPLED RECEPTOR; METHADONE; METHANANDAMIDE; REGULATOR PROTEIN; TV 130; VANILLOID RECEPTOR 1; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; RETINA S ANTIGEN;

ADVERSE OUTCOME; ALLODYNIA; ANALGESIA; ANTINOCICEPTION; ARTICLE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CONSTIPATION; DRUG DEPENDENCE; HYPOTHERMIA; NEUROCHEMISTRY; NOCICEPTION; PAIN; PAIN SEVERITY; PSYCHOLOGICAL ASPECT; RESPIRATION DEPRESSION; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ARRESTINS; CANNABINOIDS; DRUG DESIGN; HUMANS; PAIN; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, MU;

EID: 84930278822     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-41199-1_22     Document Type: Article

References (95)

1. Ahn KH, Mahmoud MM, Shim JY, Kendall DA (2013) Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem 288:9790-9800
2. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG, Lefkowitz RJ (1992) Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267:17882-17890
3. Bailey CP, Kelly E, Henderson G (2004) Protein kinase C activation enhances morphine-induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons. Mol Pharmacol 66:1592-1598
4. Bailey CP, Oldfield S, Llorent J, Caunt CH, Teschemacher AG, Roberts L, McArdle CA, Smith FL, Dewy WL, Kelly E, Henderson G (2009) Involvement of PKC alpha and G-proteincoupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158:157-164
5. Bohn LM, Raehal KM (2006) Opioid receptor signaling: relevance for gastrointestinal therapy. Curr Opin Pharmacol 6:559-563
6. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498
7. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723
8. Bohn LM, Gainetdinov RR, Caron MJ (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:10494-10500
9. Bohn LM, Gainetdinov RR, Caron MJ (2004) G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. Neuromolecular Med 5:41-50
10. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK (2008) Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/-mice. Behav Pharmacol 19:298-307
11. Brennan F, Carr DB, Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105:205-221
12. Bychkov E, Zurkovsky L, Garret MB, Ahmed MR, Gurevich EV (2012) Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum. PLoS One 7:e48912. doi:10.1371/journal.pone. 0048912
13. Celver JP, Lowe J, Kovoor A, Gurevich VV, Chavkin C (2001) Threonine 180 is required for G-protein-coupled receptor kinase 3-and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in xenopus oocytes. J Biol Chem 276:4894-4900
14. Celver J, Xu M, Jin W, Lowe J, Chavkin C (2004) Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol Pharmacol 65:528-537
15. Cox BM (2012) Recent developments in the study of opioid receptors. Mol Pharm 83:723-728
16. Craft CM, Whitmore DH, Wiechmann AF (1994) Cone arrestin identified by targeting expression of a functional family. J Biol Chem 269:4613-4619
17. Daigle TL, Kearn CS, Mackie K (2008) Rapid CB1 cannabinoid receptor desensitization defined the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54:36-44
18. Dang VC, Napier IA, Christie MJ (2009) Two distinct mechanisms mediate acute μ-opioid receptor desensitization in native neurons. J Neurosci 29:3322-3327
19. Dang VC, Chieng B, Azriel Y, Christie MJ (2011) Cellular morphine tolerance produced by βarresitn-2-dependent impairment of μ-opioid receptor resensitization. J Neurosci 31:7122-7130
20. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708-717
21. Dziaduleqicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AG, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Vecchia L, Loong Y, Lyothier I, McNair KO, Farrell C, Peacoc M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J (2007) Napthlalen-11-yl-(4-pentyloxynapthalen-1-yl) methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50:3851-3856
22. Eisinger DA, Ammer H, Schulz R (2002) Chronic morphine treatment inhibits opioid receptor desensitization and internalization. J Neurosci 22:10192-10200
23. Elmes SJR, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004) Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20:2311-2320
24. Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5:565-575
25. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144
26. Groer CE, Tidgewll K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM (2007) An opioid agonist that does not induced mu-opioid receptor/arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557
27. Groer CE, Schmid CL, Jaeger AM, Bohn LM (2011) Agonist-directed interactions with specific beta-arrestins determines mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 286:31731-31741
28. Gurevich VV, Benovic JL (2000) Arrestin: mutagenesis, expression, purification, and functional characterization. Methods Enzymol 315:422-437
29. Gurevich VV, Gurevich EV (2003) The new face of active receptor bound arrestin attracts new partners. Structure 11:1037-1042
30. Gurevich EV, Benovic JL, Gurevich VV (2002) Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109:421-436
31. Gutstein HB, Akil H (2001) Opioid analgesics. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman and Gilman's The pharmacological basis of therapeutics, 10th edn. McGraw Hill, New York, pp 569-620
32. Haberstock-Debic H, Kin KA, Yu YJ, von Zastrow (2005) Morphine promotes rapid, arrestindependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25:7847-7857
33. Henry AG, Hislop JN, Grove J, Thorn K, Marsh M, von ZastrowM(2012) Regulation of endocytic clathrin dynamics by cargo ubiquitination. Dev Cell 23:519-532
34. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004) Selecitve activation of cannabinoid CB2 receptors suppresses hyperalgeisa evoked by intradermal capsaicin. J Pharmacol Exp Ther 308:446-453
35. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontinin A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-1112
36. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
37. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP (2006) CB2 cannabinoid receptor mediation of nociception. Pain 122:36-42
38. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 recpetor agonist palmitoylethanolamine in visceral and somatic inflammatory pain. Pain 76:189-199
39. Jiang B, Shi Y, Li H, Kang L, Ma L (2006) Decreased morphine analgesia in rat overexpressing beta-arrestin 2 at periaqueductal gray. Neurosci Lett 400:150-153
40. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, Mackie K (1999) Distinct domains of the CB1 cannaniboid receptor mediate desensitizaiton and internalization. J Neurosci 15:3773-3780
41. Kang M, Maguma HT, Smith TH, Ross GR, Dewy WL, Akbarali HI (2012) The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guina pig gastrointestinal tract. J Pharmacol Exp Ther 340:567-576
42. Kelly S, Chapman V (2001) Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 86:3061-3064
43. Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19-26
44. Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306
45. Koch T, Brandenburg LO, Liang Y, Schulz S, Beyer A, Schröder H, Höllt V (2004) Phospholipase D2 modulates agonist-induced mu-opioid receptor desensitization and resensitization. J Neurochem 88:680-688
46. Kovoor A, Nappey V, Kieffer BL, Chavkin C (1997) Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arresitn2 in xenopus oocytes. J Biol Chem 272:27605-27611
47. Kovoor A, Celver JP, Wu A, Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54:704-711
48. LaBuda CJ, Koblish M, Little PH (2005) Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527:172-174
49. Lam H, Maga M, Pradhan A, Evans CJ, Maidment NT, Hales TG, Walwyn W (2011) Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2. Mol Pain 7:24
50. Lamb K, Tidgewell K, Simpson DS, Bohn LM, Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology. Drug Alcohol Depend 121:181-188
51. Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid receptor. J Biol Chem 277:15729-15735
52. Li Y, Liu X, Liu C, Kang J, Yang J, Pei G, Wu C (2009) Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter. Int J Mol Sci 10:954-963
53. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ (1990) Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science 248:1547-1550
54. Lowe JD, Celver JP, Gurevich VV, Chavkin C (2002) mu-Opioid receptors desensitize less rapidly than delta-opioid receptors due to less efficient activation of arrestin. J Biol Chem 277:15729-15735
55. Macey TA, Lowe JD, Chavkin C (2006) Mu opioid receptor activation of ERK 1/2 is GRK3 and arrestin dependent in striatal neurons. J Biol Chem 281:34515-34524
56. Malan TP, Ibrahim MM, Deng JF, Liu A, Mata HP, Vanderah T, Porreca R, Makriyannis A (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245
57. Malik R, Soh UJ, Trejo J, Marchese A (2012) Novel roles for the E3 ubiquitin ligase atrophininteracting protein 4 and signal transduction adaptor molecule 1 in G protein-coupled receptor signaling. J Biol Chem 287:9013-9027
58. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, LeMeur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioidreceptor gene. Nature 383:819-823
59. McPherson J, Rivero G, Baptist M, Lorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey COP, Rosethorne EM, Charlton SJ, Henderson G, Kelly E (2010) μ-opioid receptors: correlation of agonist efficacy for signaling with ability to activate internalization. Mol Pharmacol 78:756-766
60. Mittal N, Tan M, Egbuta O, Desai N, Crawford C, Xie CW, Evans C, WalwynW(2012) Evidence that behavioral phenotypes of morphine in β-arrs-/-mice are due to the unmaking of JNK signaling. Neuropscyhopharmacology 37:1953-1962
61. Molinari P, Vezzi V, Sbraccia M, Gró C, Riitano D, Ambrosio C, Casella I, Costa T (2010) Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285:12522-12535
62. Murakami A, Yajima T, Sakuma H, McLaren MJ, Inana G (1993) X-arrestin: a new retinal arrestin mapping to the X chromosome. FEBS Lett 334:203-209
63. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ (2012) β-arrestin2 regulated cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry 71:714-724
64. Palazzo E, Livio L, de Novellis V, Rossi F, Maione S (2010) The role of cannabinoid receptor in the descending modulation of pain. Pharmaceuticals 3:2661-2673
65. Pasternak GW (2013) Molecular biology of opioid analgesia. J Pain Symptom Manage 29:2-9
66. Patierno S, Anselmi L, Jaramill I, Scott D, Garcia R, Sternini C (2011) Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation. Gastroenterology 140:618-626
67. Pertwee RG (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7:E625-654
68. Por ED, Bierbower SM, Berg KA, Gomez R, Akopian AN, Wetsel WC, Jeske NA (2012) β-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 287:37552-37563
69. Por ED, Gomez R, Akopian AN, Jeske NA (2013) Phosphorylation regulates TRPV1 association with β-arrestin-2. Biochem J 451:101-109
70. Przewlocka B, Sieja A, Starowicz K, Maj M, Bilecki W, Przewlocki R (2002) Knockdown of spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance and allodynia in rat. Neurosci Lett 325:107-110
71. Qiu Y, Law PY, Loh HH (2003) Mu-opioid receptor desensitization: role of receptor phosphorylation, internalization and representation. J Biol Chem 278:36733-36739
72. Quillinan N, Lau EK, Virk M, von Zastrow M, Williams JT (2011) Recovery from μ-opioid receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 31:4434-4443
73. Raehal KM, Bohn LM (2011) The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 63:1001-1019
74. Raehal KM, Walker JK, Bohn LM (2005) Morphine side effects in beta-arresitn2 knockout mice. J Pharmacol Exp Ther 314:1195-1201
75. Raehal KM, Schmid CL, Groer CE, Bohn LM (2011) Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63 (4):1001-1019
76. Rea K, Roche M, Finn DP (2007) Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol 152:633-648
77. Roy S, Liu HC, Loh HH (1998) Mu-opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. Brain Res 56:281-283
78. Schmidlin F, Roosterman D, Bunnett NW (2003) The third intracellular loop and carboxyl tail of neurokinin 1 and 3 receptors determine interactions with beta-arrestins. Am J Physiol Cell Physiol 285:C945-C958
79. Shinohara T, Dietzschold B, Craft CM, Wistow G, Early JJ, Donoso LA, Horwitz J, Tao R (1987) Primary and secondary structure of bovine retinal S antigen (48-kDa protein). Proc Natl Acad Sci USA 84:6975-6979
80. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. 16:8057-8066.
81. Smith TH, Sim-Selley LJ, Selley DE (2010) Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160):454-66.
82. Sokal DM, Elmes SJR, Kendall DA, Chapman V (2003) Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurons via activation of CB2 receptors in anaesthetized rats. Neuropharmacol 45:404-411
83. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549
84. Suplita RL 2nd, Gutierrez T, Fegley D, Piomelli D, Hohmann AG (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacol 50:372-379
85. SvÍzenská I, Dubový P, Sulcová A (2008) Cannabinoid receptor 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-a short review. Pharmacol Biochem Behav 90:501-511
86. Walwyn WM, Wei W, Xie CW, Chiu K, Kieffer BL, Evans CJ, Maidment NT (2006) Mu opioid receptor-effector coupling and trafficking in dorsal root ganglia neurons. Neuroscience 142:493-503
87. Walwyn W, Evans CJ, Hales TG (2007) Beat-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci 27:5092-5104
88. Whistler JL, von Zastrow M (1998) Morphine-activated opioid receptor eludes desensitization by beta-arrestin. Proc Natl Acad Sci USA 95:9914-9919
89. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746
90. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223-254
91. Yamaki K, Takahashi Y, Sakuragi S, Matsubara K (1987) Molecular cloning of the S-antigen cDNA from bovine retina. Biochem Biophys Res Comm 142:904-910
92. Yang CH, Huang HW, Chen KH, Chen YS, Sheen-Chen SM, Lin CR (2011) Antinociceptive potentiation and attenuation of tolerance by intrathecal β-arrestin 2 small interfering RNA in rats. Br J Anaesth 107:774-781
93. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, Caron MG (1998) Roler for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162
94. Zhang L, Zhao H, Qui Y, Loh HH, Law PY (2008) Src phosphorylation of μ-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signal. J Biol Chem 284:1990-2000
95. Zimmer A, Zimmer AM, Hohmann AG, Herkenhan M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785